Pharmaceuticals
ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting
SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster presentation at American Association for Cancer Resea...
2025-04-28 09:00
4105
Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 27, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its partner, Pfizer, has presented preclinical data on PF-08052666 (HBM9033; SGN-MesoC2), a first-in-class topoisome...
2025-04-28 08:00
2554
ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups
Ono Partnering with LabCentral and MBC BioLabs for Fifth Consecutive Year CAMBRIDGE, Mass., April 26, 2025 /PRNewswire/ -- ONO PHARMA USA today announced partnerships with LabCentral inCambridge, Mass., and MBC BioLabs in San Francisco and San Carlos, CA to award each organization one Golden Tick...
2025-04-27 00:00
3513
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) ...
2025-04-25 17:44
3125
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
CHENGDU, China, April 24, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CD...
2025-04-25 11:37
3073
Primo's Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement ...
2025-04-24 23:00
3012
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
SHANGHAI, April 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that thePhase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined with toripalimab in patients with locally advanced...
2025-04-24 20:00
2867
Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025
* DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors and BTK degraders was selected for oral presentation ...
2025-04-24 18:38
3144
Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis - - MM-II recently granted Fast Track Designation ...
2025-04-24 14:31
3010
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeti...
2025-04-23 21:35
3471
Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
HANGZHOU, China, April 22, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...
2025-04-23 15:03
2443
Samsung Biologics reports first quarter 2025 financial results
* Recorded Q1'25 consolidated revenue of KRW 1.3 trillion * Recorded Q1'25 consolidated operating profit of KRW 486.7 billion * Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, ...
2025-04-23 14:46
3678
WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
* Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals * Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resear...
2025-04-22 16:30
5103
BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy
CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 3...
2025-04-21 20:30
4522
Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025
ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Associatio...
2025-04-21 19:00
2972
DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies
SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific anti...
2025-04-21 15:35
2841
Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...
2025-04-18 22:10
4961
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...
2025-04-18 19:39
4117
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor...
2025-04-18 14:30
5600
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or64Cu) isotope. * The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capaci...
2025-04-17 21:01
3941
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 287 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 280 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 276 media titles]
2026-10-15 12:59
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Most Read
Amap and Sands China mark the delivery of the first Tutu robots, with expected indoor navigation and 3D resort previews
2026-10-10 16:43
14190
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
11129
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
9430